[Recommendations of the French Society for the Control of Cancers and Leukemias in Children for the treatment of tumor lysis syndrome: results of a pediatric survey].
Bertrand
Y
Y
Service d'hématologie pédiatrique, hôpital Debrousse, Lyon, France. yves.bertrand@chu-lyon.fr
D000293:Adolescent; D000963:Antimetabolites / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002648:Child; D002675:Child, Preschool; D005260:Female; D005500:Follow-Up Studies; D019337:Hematologic Neoplasms / Q000188:drug therapy*; D006801:Humans; D007223:Infant; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy; D016393:Lymphoma, B-Cell / Q000188:drug therapy; D016399:Lymphoma, T-Cell / Q000188:drug therapy; D008297:Male; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy; D011994:Recombinant Proteins; D012307:Risk Factors; D015275:Tumor Lysis Syndrome / Q000188:drug therapy*; D014503:Urate Oxidase / Q000627:therapeutic use*
D000963:Antimetabolites; D000970:Antineoplastic Agents; D011994:Recombinant Proteins; C469709:rasburicase; D014503:Urate Oxidase